Decision Resources one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians and patients respond to different marketing messages when considering which asthma medicine to use. Physicians indicate that brands conveying messages of improvements in patient-centered outcomes such as number of symptom-free days, reduction in acute exacerbations and quality of life receive more positive feedback than messages directed at particular drug attributes such as method of delivery, device characteristics and dosing frequency. Schering-Plough's marketing message for Asmanex was ranked as the most appealing to physicians as compared with the other brand messages. Asmanex's marketing speaks to physicians' interest in prescribing treatments that effectively address patients' symptoms throughout the entire day.

The new report entitled Brands & Strategies Asthma also finds that patients, on the other hand, respond most favorably to the marketing messages for Advair and Xolair which focus on symptom improvement and asthma control.

Advair's message of "Fewer Asthma Symptoms, Better Breathing," appeals to a higher percentage of pulmonologists than of primary care physicians (PCPs). Surprisingly, PCPs find Xolair's message of "Allergic asthma: Do you have as much control as you should?" more appealing than pulmonologists, even though pulmonologists prescribe this drug more than PCPs do.

"PCPs treat numerous patients that have both asthma and allergic conditions such as allergic rhinitis and chronic sinusitis," said Regina Jammen, M.S., analyst at Decision Resources. "Xolair's message of control regarding allergic asthma resonates with these physicians likely as a result of the frequency with which the physicians encounter this clinical scenario."

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies so they can better position themselves in a market and plan future strategy based on what competitors are doing. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to make informed decisions about their brands and next-steps.

About Decision Resources

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Heather Hilty                           Elizabeth Marshall   Decision Resources                      Decision Resources, Inc.   781-296-2536                            781-296-2563   hhilty@dresources.com                   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Heather Hilty of Decision Resources, +1-781-296-2536,
hhilty@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections

View Now